<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418259</url>
  </required_header>
  <id_info>
    <org_study_id>KOSfordryeyes2018</org_study_id>
    <nct_id>NCT03418259</nct_id>
  </id_info>
  <brief_title>Kinetic Oscillation Stimulation (KOS) as a Treatment of Keratoconjunctivitis Sicca (Dry Eye Syndrome)</brief_title>
  <official_title>Study of Patients With Dry Eyes, Keratoconjunctivitis Sicca, During Treatment With Kinetic Oscillation Stimulation (KOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kallmark Clinic (KällmarksKliniken)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate how treatment with Kinetic Oscillation Stimulation
      (KOS) in the nasal cavity in patients with Keratoconjunctivitis sicca can relieve these
      symtoms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 6, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded randomised clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Placebo device</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular surface disease index, OSDI</measure>
    <time_frame>Change from Baseline Ocular surface disease index at two weeks.</time_frame>
    <description>12-item scale for the assessment of symptoms related to dry eye disease and their effect on vision. Scale 0-100, normal value range 0-12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Noninvasive breakup time, NIBUT</measure>
    <time_frame>Change from Baseline Noninvasive breakup time at two weeks.</time_frame>
    <description>Assessment of tear film stability. Normal value at least 11 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibography</measure>
    <time_frame>Change from Baseline Meibo scale value at two weeks.</time_frame>
    <description>Imaging study method for directly visualizing the morphology of Meibomian glands in vivo. Fat amount in the Meibomian glands is quantified and stated in percent. A Meibo scale value over 25 % is considered abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenol Red Thread Test, PRT</measure>
    <time_frame>Change from Baseline lacrimation assessed with Phenol Red Thread Test value at two weeks.</time_frame>
    <description>Measurement of lacrimation, stated in millimetres. Normal value is 12-20 millimetres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear (lacrimal) meniscus height</measure>
    <time_frame>Change from Baseline Tear (lacrimal) meniscus height at two weeks.</time_frame>
    <description>Tear meniscus height measured medially on the lower eyelid. Stated in millimetres. Normal value is over 0,2 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lissamin green test</measure>
    <time_frame>Change from Baseline spread of dry cell patches quantified with Lissamin green test at two weeks.</time_frame>
    <description>A strip of paper containing lissamine green is diluted with saline, and then dropped into the eye. The colour of the paper will disclose any dry cell patches in the eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal staining with fluorescein</measure>
    <time_frame>Change from Baseline Efron Grading Scale value at two weeks.</time_frame>
    <description>Fluorescein is used to describe the severity of damaged epithelial cells on cornea. Efron Grading Scale, 1-5. 0 is normal value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Keratoconjunctivitis Sicca (KCS)</condition>
  <arm_group>
    <arm_group_label>Active KCS Medical Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive KCS Medical Device</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KCS Medical Device</intervention_name>
    <description>Patient treated 6 times with the Active KCS Medical Device during 2 weeks.</description>
    <arm_group_label>Active KCS Medical Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KCS Medical Device</intervention_name>
    <description>Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.</description>
    <arm_group_label>Inactive KCS Medical Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ocular surface disease index, OSDI &gt; 12 points.

          -  Non-invasive breakup time, NIBUT &lt; 11 seconds.

        Exclusion Criteria:

          -  Ocular surface disease index, OSDI &lt; 12 points.

          -  Non-invasive breakup time, NIBUT &gt; 11 seconds.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Erik Juto, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Science, Intervention and Technology (CLINTEC), H9, Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan-Erik Juto, M.D., Ph.D.</last_name>
    <phone>+46768830709</phone>
    <email>jan-erik.juto@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Källmarkskliniken</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Källmark, B.Sc., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Jan-Erik Juto</investigator_full_name>
    <investigator_title>Principal Investigator, M.D., Ph.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

